Remitly Global (NASDAQ:RELY) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.08) by 412.5 percent. The company reported quarterly sales of $121.24 million which beat the analyst consensus estimate of $108.78 million by 11.46 percent.
EyePoint Pharmaceuticals Sponsored Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) Posted to Clinical Trials Website; Study is Not Yes Recruiting
https://clinicaltrials.gov/ct2/show/NCT05381948